Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Download references

This article is part of the supplement: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor

Highly Accessed

Biology of RANK, RANKL, and osteoprotegerin

Brendan F Boyce* and Lianping Xing

Arthritis Research & Therapy 2007, 9(Suppl 1):S1  doi:10.1186/ar2165